(State or other jurisdiction of incorporation or organization) | (I.R.S. Employer Identification No.) |
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Title of each class | Trading Symbol(s) | Name of each exchange on which registered | ||||||||||||
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). | |||||||||||
Emerging growth company | |||||||||||
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨ |
10.1 | ||||||||||||||
99.1 | ||||||||||||||
99.2 | ||||||||||||||
104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) |
Payment Date | Principal Amortization Payment (% of Outstanding Amount of Term Loans as of the Second Amendment Effective Date) | ||||
December, 2021 | 0.625% | ||||
March, 2022 | 0.625% | ||||
June, 2022 | 0.625% | ||||
September, 2022 | 0.625% | ||||
December, 2022 | 0.625% | ||||
March, 2023 | 0.625% | ||||
June, 2023 | 0.625% | ||||
September, 2023 | 0.625% | ||||
December, 2023 | 1.250% | ||||
March, 2024 | 1.250% |
June, 2024 | 1.250% | ||||
September, 2024 | 1.250% | ||||
December, 2024 | 1.250% | ||||
March, 2025 | 1.250% | ||||
June, 2025 | 1.250% | ||||
September, 2025 | 1.250% | ||||
December, 2025 | 1.250% | ||||
March, 2026 | 1.250% | ||||
June, 2026 | 1.250% | ||||
September, 2026 | 1.250% | ||||
December, 2026 | 1.250% | ||||
March, 2027 | 1.250% | ||||
June, 2027 | 1.250% | ||||
Term Facility Maturity Date | Outstanding Principal Balance of Term Loans | ||||
For the Three-Month Periods Ended March 31, | ||||||||||||||
2025 | 2024 | |||||||||||||
Net service revenue | $ | 594,781 | $ | 571,414 | ||||||||||
Operating expenses: | ||||||||||||||
Cost of service, inclusive of depreciation | 334,050 | 321,537 | ||||||||||||
General and administrative expenses: | ||||||||||||||
Salaries and benefits | 131,968 | 127,946 | ||||||||||||
Non-cash compensation | 6,223 | 7,433 | ||||||||||||
Merger-related expenses | 16,769 | 20,667 | ||||||||||||
Depreciation and amortization | 4,447 | 4,271 | ||||||||||||
Other | 57,965 | 57,941 | ||||||||||||
Total operating expenses | 551,422 | 539,795 | ||||||||||||
Operating income | 43,359 | 31,619 | ||||||||||||
Other income (expense): | ||||||||||||||
Interest income | 2,873 | 1,727 | ||||||||||||
Interest expense | (6,422) | (8,119) | ||||||||||||
Equity in earnings from equity method investments | 1,794 | 910 | ||||||||||||
Gain on equity method investment | 48,093 | — | ||||||||||||
Miscellaneous, net | 1,508 | 1,090 | ||||||||||||
Total other income (expense), net | 47,846 | (4,392) | ||||||||||||
Income before income taxes | 91,205 | 27,227 | ||||||||||||
Income tax expense | (29,384) | (12,633) | ||||||||||||
Net income | 61,821 | 14,594 | ||||||||||||
Net income attributable to noncontrolling interests | (809) | (194) | ||||||||||||
Net income attributable to Amedisys, Inc. | $ | 61,012 | $ | 14,400 | ||||||||||
Basic earnings per common share: | ||||||||||||||
Net income attributable to Amedisys, Inc. common stockholders | $ | 1.86 | $ | 0.44 | ||||||||||
Weighted average shares outstanding | 32,793 | 32,670 | ||||||||||||
Diluted earnings per common share: | ||||||||||||||
Net income attributable to Amedisys, Inc. common stockholders | $ | 1.84 | $ | 0.44 | ||||||||||
Weighted average shares outstanding | 33,218 | 32,979 |
March 31, 2025 | December 31, 2024 | ||||||||||
ASSETS | |||||||||||
Current assets: | |||||||||||
Cash and cash equivalents | $ | 284,881 | $ | 303,242 | |||||||
Patient accounts receivable | 319,639 | 296,075 | |||||||||
Prepaid expenses | 17,410 | 13,072 | |||||||||
Other current assets | 12,034 | 19,694 | |||||||||
Total current assets | 633,964 | 632,083 | |||||||||
Property and equipment, net of accumulated depreciation of $103,758 and $100,890 | 40,186 | 42,108 | |||||||||
Operating lease right of use assets | 80,905 | 81,500 | |||||||||
Goodwill | 1,213,888 | 1,213,888 | |||||||||
Intangible assets, net of accumulated amortization of $19,949 and $18,787 | 80,199 | 81,155 | |||||||||
Other assets | 135,432 | 87,980 | |||||||||
Total assets | $ | 2,184,574 | $ | 2,138,714 | |||||||
LIABILITIES AND EQUITY | |||||||||||
Current liabilities: | |||||||||||
Accounts payable | $ | 28,705 | $ | 39,956 | |||||||
Payroll and employee benefits | 131,722 | 151,995 | |||||||||
Accrued expenses | 162,180 | 152,564 | |||||||||
Termination fee paid by UnitedHealth Group | 106,000 | 106,000 | |||||||||
Current portion of long-term obligations | 37,579 | 37,968 | |||||||||
Current portion of operating lease liabilities | 25,845 | 25,909 | |||||||||
Total current liabilities | 492,031 | 514,392 | |||||||||
Long-term obligations, less current portion | 332,947 | 339,313 | |||||||||
Operating lease liabilities, less current portion | 55,642 | 56,111 | |||||||||
Deferred income tax liabilities | 58,032 | 48,051 | |||||||||
Other long-term obligations | 848 | 882 | |||||||||
Total liabilities | 939,500 | 958,749 | |||||||||
Equity: | |||||||||||
Preferred stock, $0.001 par value, 5,000,000 shares authorized; none issued or outstanding | — | — | |||||||||
Common stock, $0.001 par value, 60,000,000 shares authorized; 38,381,255 and 38,307,521 shares issued; 32,818,871 and 32,776,148 shares outstanding | 38 | 38 | |||||||||
Additional paid-in capital | 825,138 | 818,201 | |||||||||
Treasury stock, at cost, 5,562,384 and 5,531,373 shares of common stock | (477,718) | (474,854) | |||||||||
Retained earnings | 852,168 | 791,156 | |||||||||
Total Amedisys, Inc. stockholders’ equity | 1,199,626 | 1,134,541 | |||||||||
Noncontrolling interests | 45,448 | 45,424 | |||||||||
Total equity | 1,245,074 | 1,179,965 | |||||||||
Total liabilities and equity | $ | 2,184,574 | $ | 2,138,714 |
For the Three-Month Periods Ended March 31, | ||||||||||||||
2025 | 2024 | |||||||||||||
Cash Flows from Operating Activities: | ||||||||||||||
Net income | $ | 61,821 | $ | 14,594 | ||||||||||
Adjustments to reconcile net income to net cash used in operating activities: | ||||||||||||||
Depreciation and amortization (inclusive of depreciation included in cost of service) | 6,787 | 6,138 | ||||||||||||
Non-cash compensation | 6,844 | 7,886 | ||||||||||||
Amortization and impairment of operating lease right of use assets | 8,645 | 8,566 | ||||||||||||
(Gain) loss on disposal of property and equipment | (34) | 4 | ||||||||||||
Gain on equity method investment | (48,093) | — | ||||||||||||
Deferred income taxes | 9,981 | 2,594 | ||||||||||||
Equity in earnings from equity method investments | (1,794) | (910) | ||||||||||||
Amortization of deferred debt issuance costs | 248 | 248 | ||||||||||||
Return on equity method investments | 2,320 | 170 | ||||||||||||
Changes in operating assets and liabilities: | ||||||||||||||
Patient accounts receivable | (23,564) | (46,806) | ||||||||||||
Other current assets | 3,480 | (1,696) | ||||||||||||
Operating lease right of use assets | (1,186) | (1,042) | ||||||||||||
Other assets | 88 | 155 | ||||||||||||
Accounts payable | (10,913) | 8,652 | ||||||||||||
Accrued expenses | (10,658) | 3,029 | ||||||||||||
Other long-term obligations | (34) | (591) | ||||||||||||
Operating lease liabilities | (7,625) | (7,532) | ||||||||||||
Net cash used in operating activities | (3,687) | (6,541) | ||||||||||||
Cash Flows from Investing Activities: | ||||||||||||||
Proceeds from the sale of deferred compensation plan assets | 27 | 21 | ||||||||||||
Proceeds from the sale of property and equipment | 15 | — | ||||||||||||
Purchases of property and equipment | (1,215) | (2,670) | ||||||||||||
Investments in technology assets | (201) | (223) | ||||||||||||
Investment in equity method investee | — | (196) | ||||||||||||
Net cash used in investing activities | (1,374) | (3,068) | ||||||||||||
Cash Flows from Financing Activities: | ||||||||||||||
Proceeds from the issuance of stock upon exercise of stock options | 93 | — | ||||||||||||
Shares withheld to pay taxes on non-cash compensation | (2,864) | (617) | ||||||||||||
Noncontrolling interest contributions | — | 1,764 | ||||||||||||
Noncontrolling interest distributions | (785) | (756) | ||||||||||||
Principal payments of long-term obligations | (9,744) | (8,941) | ||||||||||||
Net cash used in financing activities | (13,300) | (8,550) | ||||||||||||
Net decrease in cash, cash equivalents and restricted cash | (18,361) | (18,159) | ||||||||||||
Cash, cash equivalents and restricted cash at beginning of period | 303,242 | 138,863 | ||||||||||||
Cash, cash equivalents and restricted cash at end of period | $ | 284,881 | $ | 120,704 | ||||||||||
Supplemental Disclosures of Cash Flow Information: | ||||||||||||||
Cash paid for interest | $ | 6,177 | $ | 8,188 | ||||||||||
Cash paid for income taxes, net of refunds received | $ | 907 | $ | 828 | ||||||||||
Cash paid for operating lease liabilities | $ | 8,811 | $ | 8,574 | ||||||||||
Cash paid for finance lease liabilities | $ | 4,121 | $ | 2,236 | ||||||||||
Supplemental Disclosures of Non-Cash Activity: | ||||||||||||||
Right of use assets obtained in exchange for operating lease liabilities | $ | 7,006 | $ | 7,173 | ||||||||||
Right of use assets obtained in exchange for finance lease liabilities | $ | 3,158 | $ | 4,326 | ||||||||||
Reductions to right of use assets resulting from reductions to operating lease liabilities | $ | 75 | $ | 168 | ||||||||||
Reductions to right of use assets resulting from reductions to finance lease liabilities | $ | 415 | $ | 496 | ||||||||||
Days revenue outstanding (1) | 45.7 | 54.1 |
For the Three-Month Periods Ended March 31, | |||||||||||
2025 | 2024 | ||||||||||
Net income attributable to Amedisys, Inc. | $ | 61,012 | $ | 14,400 | |||||||
Add: | |||||||||||
Income tax expense | 29,384 | 12,633 | |||||||||
Interest expense, net | 3,549 | 6,392 | |||||||||
Depreciation and amortization | 6,787 | 6,138 | |||||||||
Certain items(1) | (31,903) | 20,296 | |||||||||
Adjusted EBITDA(2)(5) | $ | 68,829 | $ | 59,859 |
For the Three-Month Periods Ended March 31, | |||||||||||
2025 | 2024 | ||||||||||
Net income attributable to Amedisys, Inc. | $ | 61,012 | $ | 14,400 | |||||||
Add: | |||||||||||
Certain items(1) | (19,430) | 19,548 | |||||||||
Adjusted net income attributable to Amedisys, Inc.(3)(5) | $ | 41,582 | $ | 33,948 |
For the Three-Month Periods Ended March 31, | |||||||||||
2025 | 2024 | ||||||||||
Net income attributable to Amedisys, Inc. common stockholders per diluted share | $ | 1.84 | $ | 0.44 | |||||||
Add: | |||||||||||
Certain items(1) | (0.59) | 0.59 | |||||||||
Adjusted net income attributable to Amedisys, Inc. common stockholders per diluted share(4)(5) | $ | 1.25 | $ | 1.03 |
For the Three-Month Periods Ended March 31, | |||||||||||
2025 | 2024 | ||||||||||
(Income) Expense | (Income) Expense | ||||||||||
Certain Items Impacting General and Administrative Expenses: | |||||||||||
Merger-related expenses | $ | 16,769 | $ | 20,667 | |||||||
Certain Items Impacting Total Other Income (Expense): | |||||||||||
Other (income) expense, net (includes $48,093 gain on equity method investment) | (48,672) | (371) | |||||||||
Total | $ | (31,903) | $ | 20,296 | |||||||
Net of tax | $ | (19,430) | $ | 19,548 | |||||||
Diluted EPS | $ | (0.59) | $ | 0.59 |
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
>U:7:J-M$%FR#VJ\:N.PA1UI335ZTIZT
MP"BBB@ HHHH **** "BB@4 +1ZT44P,_4_\ CT;ZU3M_NU;U3BU/UJK;]!6<
MC,N)4G:HTZ5)0AA1113 0DTF:7&:-M "9HI<4A% !FES28HQ0(6CH: *#0QC
MJ*:/6E!H0"T444P"@T44 )12TE "4M%)0(**,TE( I*6B@!***0F@ -)110
M449HS2 **,TE :2EI* $HHH- "4AI:0FD(**2B@ I*7--S2 6DI,T9H 6FF
MG9IIH ;BE%!XHI '2C-(:,TR0I*6DH!B49HI#ZT +TH!%,)R*13B@!YI*04&
M@ - S2$\TF:!#LT9I@.*7- "Y-&:*2@ S2$T4UC2; 7-&:9NP*3=S2Y@'DFC
M--SQ29I@!Y-+VIN:0FD)#L\49K'O_$FE:;GS[N/(_A!K"F^(NFKQ& WN2:I#
MLV=GF@'/'6O/Y/B,A;$8B /3.:9_PGEY)_JE@;_=-#N/E9Z&!S7"^,]4\VZ6
MSC.$AX)'<]ZI/XZOTX(1<] &>>(I%.NZ)C_$/6MW
M1[[48?#\VVV26Q61878#]YACRBGT-= -0LM9NM/BN;5(KVT67;92=,@#8I]O
M:O/J8BI3GM='7&C&45K8\[.#C!I2,=^U=GKNA1W%_(S+%!<8BC*0<+YK] *IMC.:PJ/4WBM!E^V;9L==I
MQ7-7<%Q-'%##)Y2XP2*WYSO0H#DTL-J-@R!G%E=DW0?6J